Vivek Ra­maswamy trades top ex­ecs and adds stealthy vant to $3B sale, while his new part­ner toss­es My­ovant $350M

Roivant chief Vivek Ra­maswamy will pick up his $3 bil­lion check from Sum­it­o­mo Dainip­pon in ex­change for his stake in 5 of his start­up vants — along with an op­tion on 6 more as well as an op­er­a­tions team to over­see their work. And as they fol­low through on the deal, we’re learn­ing the iden­ti­ty of the 5th biotech in the um­brel­la deal — which turns out to be a stealth com­pa­ny which Ra­maswamy bought up to pur­sue a gene ther­a­py for cys­tic fi­bro­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER